Maynard Um
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Coya Therapeutics (COYA)
-
-
-
-
-
-
-
Lucid Capital Markets Reiterates Buy Rating on Coya Therapeutics (COYA), PT $20
-
-
-
-
-
-
-
Coya Therapeutics publishes research linking inflammation to Parkinson's disease
-
-
-
-
-
-
-
Coya Therapeutics (COYA) Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate F
-
-
-
-
-
-
-
Coya Therapeutics (COYA) Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases
-
-
-
-
-
-
-
Coya Therapeutics (COYA) Announces 1.38M Share Offering at $7.25/sh
-
-
-
-
-
-
-
Coya Therapeutics (COYA) Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

